AbCellera shareholders elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting

AbCellera Biologics Inc.

John S. Montalbano elected with 167.3M for, 11.0M against; Peter Thiel with 131.2M for, 47.0M against.
Ratification of KPMG as auditor approved: 201.0M for, 0.3M against, 0.2M abstain.
Non-binding say-on-pay compensation approved: 159.4M for, 18.6M against, 0.4M abstain.
Total shares outstanding at record date: 288.7M; broker non-votes on director and say-on-pay: 23.0M.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AbCellera Biologics Inc. shareholders approved Election of John S. Montalbano, CFA and Peter Thiel as class III directors at the 2023-06-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

The Company’s shareholders voted for the class III directors as follows: Nominee For Against Abstain John S. Montalbano, CFA 167,257,682 10,997,867 165,946 Peter Thiel 131,151,160 47,033,189 237,146 The broker non-votes for this Proposal 1 totaled 23,048,328 common shares.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AbCellera Biologics Inc. shareholders approved Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

The votes cast at the Annual Meeting were as follows: For Against Abstain 200,983,540 299,897 186,386

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

AbCellera Biologics Inc. shareholders approved Approve on a non-binding advisory basis the compensation of the Company’s named executive officers (Say-on-Pay) at the 2023-06-15 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

The votes cast at the Annual Meeting were as follows: For Against Abstain 159,440,607 18,625,842 355,046 The broker non-votes for this Proposal 3 totaled 23,048,328 common shares.

View on SEC.gov

640 shareholder votes filed in the last 30 days. Browse all shareholder votes →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.